These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 29906114)

  • 1. Design, Synthesis, and Biological Evaluation of Pyrimido[4,5- d]pyrimidine-2,4(1 H,3 H)-diones as Potent and Selective Epidermal Growth Factor Receptor (EGFR) Inhibitors against L858R/T790M Resistance Mutation.
    Hao Y; Lyu J; Qu R; Tong Y; Sun D; Feng F; Tong L; Yang T; Zhao Z; Zhu L; Ding J; Xu Y; Xie H; Li H
    J Med Chem; 2018 Jul; 61(13):5609-5622. PubMed ID: 29906114
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structural optimization of diphenylpyrimidine scaffold as potent and selective epidermal growth factor receptor inhibitors against L858R/T790M resistance mutation in nonsmall cell lung cancer.
    Yi Y; Wang L; Zhao D; Huang S; Wang C; Liu Z; Sun H; Liu K; Ma X; Li Y
    Chem Biol Drug Des; 2018 Dec; 92(6):1988-1997. PubMed ID: 30030903
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and anticancer evaluation of 1H-pyrazolo[3,4-d]pyrimidine derivatives as potent EGFR
    Gaber AA; Bayoumi AH; El-Morsy AM; Sherbiny FF; Mehany ABM; Eissa IH
    Bioorg Chem; 2018 Oct; 80():375-395. PubMed ID: 29986185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis and biological evaluation of novel 2,4-diaryl pyrimidine derivatives as selective EGFR
    Li J; An B; Song X; Zhang Q; Chen C; Wei S; Fan R; Li X; Zou Y
    Eur J Med Chem; 2021 Feb; 212():113019. PubMed ID: 33429247
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of new thieno[3,2-d]pyrimidine derivatives targeting EGFR
    Chen Y; Yang L; Qiao H; Cheng Z; Xie J; Zhou W; Huang X; Jiang Y; Yu B; Zhao W
    Eur J Med Chem; 2020 Aug; 199():112388. PubMed ID: 32402937
    [TBL] [Abstract][Full Text] [Related]  

  • 6. YL143, a novel mutant selective irreversible EGFR inhibitor, overcomes EGFR
    Zhang Z; Zou J; Yu L; Luo J; Li Y; Tu Z; Ren X; Wei H; Song L; Lu X; Ding K
    Cancer Med; 2018 Apr; 7(4):1430-1439. PubMed ID: 29532998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Design, synthesis, and biological evaluation of hydroxamic acid-substituted 2,4-diaryl aminopyrimidines as potent EGFRT790M/L858R inhibitors for the treatment of NSCLC.
    Chen L; Zhang Y; Wang C; Tang Z; Meng Q; Sun H; Qi Y; Ma X; Li L; Li Y; Xu Y
    Bioorg Chem; 2021 Sep; 114():105045. PubMed ID: 34161879
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Structure-Guided Design of C4-alkyl-1,4-dihydro-2H-pyrimido[4,5-d][1,3]oxazin-2-ones as Potent and Mutant-Selective Epidermal Growth Factor Receptor (EGFR) L858R/T790M Inhibitors.
    Hao Y; Lyu J; Qu R; Sun D; Zhao Z; Chen Z; Ding J; Xie H; Xu Y; Li H
    Sci Rep; 2017 Jun; 7(1):3830. PubMed ID: 28630494
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rational design and synthesis of 2,4-dichloro-6-methyl pyrimidine derivatives as potential selective EGFR
    Duan L; Chu C; Huang X; Yao H; Wen J; Chen R; Wang C; Tu Y; Lv Q; Pan Q; Xu S
    Arch Pharm (Weinheim); 2024 May; 357(5):e2300736. PubMed ID: 38381049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Discovery of novel 2,4-diarylaminopyrimidine derivatives as potent and selective epidermal growth factor receptor (EGFR) inhibitors against L858R/T790M resistance mutation.
    Yan Q; Chen Y; Tang B; Xiao Q; Qu R; Tong L; Liu J; Ding J; Chen Y; Ding N; Tan W; Xie H; Li Y
    Eur J Med Chem; 2018 May; 152():298-306. PubMed ID: 29730192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis and biological evaluation of morpholine-substituted diphenylpyrimidine derivatives (Mor-DPPYs) as potent EGFR T790M inhibitors with improved activity toward the gefitinib-resistant non-small cell lung cancers (NSCLC).
    Song Z; Huang S; Yu H; Jiang Y; Wang C; Meng Q; Shu X; Sun H; Liu K; Li Y; Ma X
    Eur J Med Chem; 2017 Jun; 133():329-339. PubMed ID: 28395219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Noncovalent EGFR T790M/L858R inhibitors based on diphenylpyrimidine scaffold: Design, synthesis, and bioactivity evaluation for the treatment of NSCLC.
    Chen L; Zhang Y; Tian L; Wang C; Deng T; Zheng X; Wang T; Li Z; Tang Z; Meng Q; Sun H; Li L; Ma X; Xu Y
    Eur J Med Chem; 2021 Nov; 223():113626. PubMed ID: 34218082
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery of 5-(methylthio)pyrimidine derivatives as L858R/T790M mutant selective epidermal growth factor receptor (EGFR) inhibitors.
    Xiao Q; Qu R; Gao D; Yan Q; Tong L; Zhang W; Ding J; Xie H; Li Y
    Bioorg Med Chem; 2016 Jun; 24(12):2673-80. PubMed ID: 27131639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Novel EGFR inhibitors against resistant L858R/T790M/C797S mutant for intervention of non-small cell lung cancer.
    Wang X; Qin Z; Qiu W; Xu K; Bai Y; Zeng B; Ma Y; Yang S; Shi Y; Fan Y
    Eur J Med Chem; 2024 Nov; 277():116711. PubMed ID: 39094277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Synthesis and Fundamental Evaluation of Radioiodinated Rociletinib (CO-1686) as a Probe to Lung Cancer with L858R/T790M Mutations of Epidermal Growth Factor Receptor (EGFR).
    Fawwaz M; Mishiro K; Nishii R; Sawazaki I; Shiba K; Kinuya S; Ogawa K
    Molecules; 2020 Jun; 25(12):. PubMed ID: 32599930
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors.
    Jia Y; Yun CH; Park E; Ercan D; Manuia M; Juarez J; Xu C; Rhee K; Chen T; Zhang H; Palakurthi S; Jang J; Lelais G; DiDonato M; Bursulaya B; Michellys PY; Epple R; Marsilje TH; McNeill M; Lu W; Harris J; Bender S; Wong KK; Jänne PA; Eck MJ
    Nature; 2016 Jun; 534(7605):129-32. PubMed ID: 27251290
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of highly potent and selective EGFR
    Yang T; Zhang W; Cao S; Sun S; Cai X; Xu L; Li P; Zheng Z; Li S
    Eur J Med Chem; 2022 Jan; 228():113984. PubMed ID: 34794818
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design, synthesis and biological evaluation of potent EGFR kinase inhibitors against 19D/T790M/C797S mutation.
    Su Z; Yang T; Wang J; Lai M; Tong L; Wumaier G; Chen Z; Li S; Li H; Xie H; Zhao Z
    Bioorg Med Chem Lett; 2020 Aug; 30(16):127327. PubMed ID: 32631532
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Structure-Guided Development of Covalent and Mutant-Selective Pyrazolopyrimidines to Target T790M Drug Resistance in Epidermal Growth Factor Receptor.
    Engel J; Smith S; Lategahn J; Tumbrink HL; Goebel L; Becker C; Hennes E; Keul M; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Hengstler JG; Rauh D
    J Med Chem; 2017 Sep; 60(18):7725-7744. PubMed ID: 28853575
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel hydrazone moiety-bearing aminopyrimidines as selective inhibitors of epidermal growth factor receptor T790M mutant.
    Qin M; Wang T; Xu B; Ma Z; Jiang N; Xie H; Gong P; Zhao Y
    Eur J Med Chem; 2015 Nov; 104():115-26. PubMed ID: 26451770
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.